[go: up one dir, main page]

SG10201913073YA - Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment - Google Patents

Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment

Info

Publication number
SG10201913073YA
SG10201913073YA SG10201913073YA SG10201913073YA SG10201913073YA SG 10201913073Y A SG10201913073Y A SG 10201913073YA SG 10201913073Y A SG10201913073Y A SG 10201913073YA SG 10201913073Y A SG10201913073Y A SG 10201913073YA SG 10201913073Y A SG10201913073Y A SG 10201913073YA
Authority
SG
Singapore
Prior art keywords
combination therapy
cancer treatment
parp inhibitor
liposomal irinotecan
irinotecan
Prior art date
Application number
SG10201913073YA
Inventor
Sarah Blanchette
Daryl Drummond
Jonathan Fitzgerald
Victor Moyo
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56801880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913073Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of SG10201913073YA publication Critical patent/SG10201913073YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201913073YA 2015-08-20 2016-08-19 Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment SG10201913073YA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562207709P 2015-08-20 2015-08-20
US201562207760P 2015-08-20 2015-08-20
US201562269756P 2015-12-18 2015-12-18
US201562269511P 2015-12-18 2015-12-18
US201662308924P 2016-03-16 2016-03-16
US201662323422P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
SG10201913073YA true SG10201913073YA (en) 2020-03-30

Family

ID=56801880

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201913073YA SG10201913073YA (en) 2015-08-20 2016-08-19 Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment

Country Status (18)

Country Link
US (4) US9895365B2 (en)
EP (1) EP3337467B1 (en)
JP (1) JP7042739B2 (en)
KR (1) KR20180037210A (en)
CN (1) CN108348480A (en)
AU (1) AU2016309002B2 (en)
CA (1) CA2992789A1 (en)
ES (1) ES2848118T3 (en)
HK (1) HK1257216A1 (en)
IL (1) IL257147B (en)
MX (1) MX381475B (en)
PL (1) PL3337467T3 (en)
PT (1) PT3337467T (en)
RU (1) RU2760185C2 (en)
SG (1) SG10201913073YA (en)
SI (1) SI3337467T1 (en)
TW (1) TWI724018B (en)
WO (2) WO2017031442A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3173073T (en) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomes for drug delivery
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2016094402A1 (en) * 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
TWI778942B (en) 2015-08-21 2022-10-01 英商益普生生物製藥有限公司 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CA3001467A1 (en) 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
RU2761953C2 (en) * 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Treatment of stomach cancer using combination types of therapy containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
AU2018264992A1 (en) * 2017-05-09 2019-12-05 Merck Sharp & Dohme B.V. Combination therapies for treating cancer
JP2020520921A (en) 2017-05-18 2020-07-16 テサロ， インコーポレイテッド Combination therapy to treat cancer
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. Combination therapies for treating cancer
KR20200067164A (en) 2017-10-06 2020-06-11 테사로, 인코포레이티드 Combination therapy and uses
AU2018359863A1 (en) * 2017-11-04 2020-07-02 Aravive Biologics, Inc Methods of treating metastatic cancers using axl decoy receptors
EP3737383A4 (en) * 2018-01-12 2021-12-15 Prolynx LLC Synergistic cancer treatment
WO2019200382A1 (en) * 2018-04-13 2019-10-17 The Board Of Regents Of University Of Texas System Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
US20210205323A1 (en) * 2018-06-01 2021-07-08 Beigene, Ltd. Maintenance therapy of a parp inhibitor in treating gastric cancer
US11752139B2 (en) * 2018-12-14 2023-09-12 Athenex HK Innovative Limited Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer
CN114053271B (en) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 Pharmaceutical composition containing TSL-1502M and application thereof
CN114053415B (en) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 TSL-1502 compound medicine combination
CA3216716A1 (en) * 2021-05-03 2022-11-10 Tim BERGBREDE Composition comprising an inhibitor of mitochondrial transcription
RU2769543C2 (en) * 2021-07-21 2022-04-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Method for assessing primary response to combined chemotherapy of sporadic ovarian cancer of stages iii and iv
CN114259569B (en) * 2021-12-30 2024-02-27 中山大学附属第八医院（深圳福田） Preparation method and application of supermolecule nano-drug based on irinotecan and nilaparil
EP4209217A1 (en) * 2022-01-11 2023-07-12 Fundación Profesor Novoa Santos Method for the treatment of brca1/2 mutated cancer
CN120225196A (en) 2022-11-21 2025-06-27 富士胶片株式会社 Liposome composition containing topotecan or its salt and DNA damage repair inhibitor

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (en) 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (en) 1996-01-31 1997-08-07 Schering Ag New selective taxanes, processes for their preparation and their pharmaceutical use
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
DK1121102T3 (en) 1998-09-16 2003-08-11 Alza Corp Liposome-enclosed topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
DE60123583T2 (en) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. DEHYDRATISATION / REHYDRATISATION PROCESS FOR THE PREPARATION OF LIPOSOME
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AU6147301A (en) 2000-05-15 2001-11-26 Celgene Corp Compositions and methods for the treatment of colorectal cancer
AU2001270385B2 (en) 2000-06-30 2006-05-25 Talon Therapeutics, Inc. Liposomal antineoplastic drugs and uses thereof
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
EP1385479A4 (en) 2001-03-26 2006-12-06 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
AU2002331290A1 (en) 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Methods for the treatment of cancer with irinotecan based on cyp3a5
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP4699025B2 (en) 2002-05-15 2011-06-08 サッター・ウエスト・ベイ・ホスピタルズ Delivery of nucleic acid-like compounds
ES2341767T3 (en) 2002-05-31 2010-06-28 Transmolecular, Inc. CHEMOTHERAPY OF COMBINATION WITH CHLOROTOXINE.
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
EP2311875A1 (en) 2003-05-30 2011-04-20 Genentech, Inc. Treatment with anti-VEGF antibodies
LT3173073T (en) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomes for drug delivery
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
AP2255A (en) 2004-06-01 2011-07-21 Yakult Honsha Kk Irinotecan preparation.
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US20100189771A1 (en) 2005-10-25 2010-07-29 Lawrence Mayer Fixed ratio drug combination treatments for solid tumors
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
RS53082B (en) 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. Combination therapy with parp inhibitors
US20080146638A1 (en) 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
WO2007109184A2 (en) 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
CA2678181C (en) 2007-02-16 2016-12-13 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CA2681302C (en) 2007-03-19 2013-07-23 Dhiraj Khattar Proliposomal and liposomal compositions of poorly water-soluble compounds
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
ES2550759T3 (en) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Enhanced pharmacological platinum formulations
WO2009040426A1 (en) 2007-09-28 2009-04-02 Universitätsspital Basel Immunoliposomes for treatment of cancer
SG185954A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
WO2009073869A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
EP2259797A2 (en) 2008-03-25 2010-12-15 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
BRPI0921586A2 (en) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc human serum albumin articulators and conjugates thereof
JP2012522055A (en) 2009-03-30 2012-09-20 セルリアン・ファーマ・インコーポレイテッド Polymer-drug conjugates, particles, compositions, and related methods of use
WO2010125462A2 (en) 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
CN102666533A (en) 2009-09-15 2012-09-12 天蓝制药公司 Treatment of cancer
RU2526114C2 (en) 2009-12-03 2014-08-20 Цзянсу Хэнжуй Медицин Ко., Лтд. Irinotecan liposomes or its salts, method for preparing them
RU2576609C2 (en) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Methods of treating pancreatic cancer
AU2011268101B2 (en) 2010-06-19 2014-09-25 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
AU2011282223A1 (en) 2010-07-19 2013-03-07 Bipar Sciences, Inc. Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
CN106432495A (en) 2010-07-22 2017-02-22 加利福尼亚大学董事会 Anti-tumor antigen antibodies and methods of use
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
CN107252417A (en) 2010-12-06 2017-10-17 梅里麦克制药股份有限公司 Dosage and the administration of myocardium toxicity are prevented in the treatment using the ERBB2 targeting immunoliposomes comprising anthracycline chemotherapy agent
AU2011344865B2 (en) 2010-12-14 2017-03-09 Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
WO2012112730A2 (en) 2011-02-15 2012-08-23 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
EP3214096A3 (en) 2011-04-19 2017-10-18 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
EP2838880B1 (en) 2012-04-17 2017-12-13 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
EP2892352B1 (en) 2012-08-31 2020-12-09 Sloan Kettering Institute For Cancer Research Particles, methods and uses thereof
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
TWI641374B (en) 2013-03-27 2018-11-21 大鵬藥品工業股份有限公司 Antineoplastic agent containing low-dose irinotecan hydrochloride hydrate
JP2016529284A (en) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ Nanoparticle drug delivery system and method for treating cancer and neurotrauma
US20160303264A1 (en) 2013-10-23 2016-10-20 Merrimack Pharmaceuticals, Inc. Liposomes useful for non-invasive imaging and drug delivery
WO2016094402A1 (en) 2014-12-09 2016-06-16 Merrimack Pharmaceuticals, Inc. Treatment of breast cancer with liposomal irinotecan
WO2016168451A1 (en) 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
TWI778942B (en) 2015-08-21 2022-10-01 英商益普生生物製藥有限公司 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CA3001467A1 (en) 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
CN109640995A (en) 2016-05-18 2019-04-16 易普森生物制药有限公司 With liposome irinotecan Small Cell Lung Cancer
RU2761953C2 (en) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Treatment of stomach cancer using combination types of therapy containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Also Published As

Publication number Publication date
IL257147B (en) 2021-07-29
US20180117034A1 (en) 2018-05-03
AU2016309002A1 (en) 2018-02-08
AU2016309002B2 (en) 2021-07-29
IL257147A (en) 2018-03-29
US20200268742A1 (en) 2020-08-27
EP3337467A1 (en) 2018-06-27
US10478428B2 (en) 2019-11-19
WO2017031445A1 (en) 2017-02-23
RU2018105655A (en) 2019-09-23
PT3337467T (en) 2021-01-25
EP3337467B1 (en) 2020-12-09
US20230074866A1 (en) 2023-03-09
TW201713312A (en) 2017-04-16
HK1257249A1 (en) 2019-10-18
MX381475B (en) 2025-03-12
US11844795B2 (en) 2023-12-19
RU2018105655A3 (en) 2020-02-21
MX2018001659A (en) 2018-05-28
WO2017031442A1 (en) 2017-02-23
PL3337467T3 (en) 2021-06-14
CA2992789A1 (en) 2017-02-23
HK1257216A1 (en) 2019-10-18
RU2760185C2 (en) 2021-11-22
TWI724018B (en) 2021-04-11
CN108348480A (en) 2018-07-31
US20170049767A1 (en) 2017-02-23
JP2018528184A (en) 2018-09-27
JP7042739B2 (en) 2022-03-28
US9895365B2 (en) 2018-02-20
SI3337467T1 (en) 2021-03-31
KR20180037210A (en) 2018-04-11
ES2848118T3 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
IL257147B (en) Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
IL290149A (en) Combination therapy for cancer treatment
IL265759A (en) Therapeutic and diagnostic methods for cancer
IL266012A (en) Combination therapy for c3 inhibition
IL258931A (en) Therapeutic compounds and methods
IL255372A0 (en) Therapeutic and diagnostic methods for cancer
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
EP3519051A4 (en) Treatment cancers using combination comprising parp inhibitors
HUE057641T2 (en) Magnetic stimulation devices for therapeutic treatments
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL256799A (en) Use of a combination of dbait molecule and parp inhibitors to treat cancer
IL242021B (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
IL275517A (en) Methods and combination therapy to treat cancer
IL270011B (en) Therapeutic compounds and methods
EP3324968C0 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
IL258494A (en) Rational combination therapy for the treatment of cancer
PT3325478T (en) New therapeutic compound and use in therapy
HRP20191391T1 (en) Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201611016D0 (en) Therapeutic treatments
GB201611017D0 (en) Therapeutic treatments